Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple intrathecal doses of nusinersen (ISIS 396443) in infantile-onset spinal muscular atrophy
2017-000621-12Phase 2
- Sponsor
- Ionis Pharmaceuticals
- Start
- Feb 2017
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Ionis Pharmaceuticals. Primary endpoint: Improvement in motor milestones.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2017-000621-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000621-12.